2,3-Bis(benzyloxy)butanedioic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3-Bis(benzyloxy)butanedioic acid
• 英文别名: 2,3-bis(phenylmethoxy)butanedioic acid
• 化学式: C₁₈H₁₈O₆
• 分子量: 330.3
• InChiKey: ZRRDKHFYTWVMFV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  93.1
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11bR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11b-HEXAHYDRO-1H-PYRIDO[2,1-a]ISOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE)
  申请人：Neurocrine Biosciences, Inc.

  公开号：US20170183346A1

  公开（公告）日：2017-06-29

  Provided herein are processes for the preparation of (S)-(2R,3R,11bR-3-isobuty-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.

  本文提供了一种制备(S)-(2R,3R,11bR-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基)2-氨基-3-甲基丁酸二(对甲苯磺酸盐)或其溶剂结晶体、水合物或多晶形态的方法。
• Tramadol analogs and uses thereof
  申请人：SEPRACOR INC.

  公开号：US20030171440A1

  公开（公告）日：2003-09-11

  Compounds of formula I are effective in treating disorders modulated by opiate receptor activity and/or monoamine activity. 1 In formula I, R 1 is selected from alkyl, aryl, alkylaryl, substituted alkyl, substituted aryl, and substituted alkylaryl; R 2 is selected from hydrogen, hydroxy, cyano, haloalkyl, glycosyl, SO 2 R 5 , and OR 5 ; R 3 and R 4 are independently selected from hydrogen and lower alkyl, or R 3 and R 4 taken together with nitrogen form a five- or six-membered heterocyclic or substituted heterocyclic ring; and R 5 is selected from alkyl, aryl, alkylaryl, substituted alkyl, substituted aryl, and substituted alkylaryl.

  式I化合物可有效用于治疗受阿片受体活性和/或单胺活性调节的疾病。在式I中，R1选择自烷基、芳基、烷基芳基、取代烷基、取代芳基和取代烷基芳基；R2选择自氢、羟基、氰基烷基、糖基、SO2R5和OR5；R3和R4独立地选择自氢和低烷基，或R3和R4与氮一起形成五元或六元杂环或取代杂环环；R5选择自烷基、芳基、烷基芳基、取代烷基、取代芳基和取代烷基芳基。
• [EN] (R)-SIBUTRAMINE SALTS AND THE PREPARATION THEREOF<br/>[FR] SELS DE (R)-SIBUTRAMINE ET LEUR PRÉPARATION
  申请人：DAE HE CHEMICAL CO LTD

  公开号：WO2010087544A1

  公开（公告）日：2010-08-05

  The present invention provides novel anhydrous crystalline (R)-sibutramine salts. Further, the present invention provides an optical resolution method of racemic sibutramine using optically active tartaric acid as an optical resolution agent, a method of preparing (R)-sibutramine salts using the same, and a racemization method of (S)-sibutramine. The anhydrous crystalline (R)-sibutramine hydrogen sulfate of the present invention is useful as an active ingredient of pharmaceutical compositions, due to having significantly high water solubility and excellent stability against moisture and high temperatures, as compared to the conventional (R,S)-sibutramine hydrochloride monohydrate. Further, the preparation method of the present invention is convenient and economic from a process point of view.

  本发明提供了新型无水结晶(R)-西布曲明盐。此外，本发明提供了使用光学活性酒石酸作为光学分辨剂的混合型西布曲明的光学分辨方法，使用相同方法制备(R)-西布曲明盐的方法，以及(S)-西布曲明的消旋化方法。本发明的无水结晶(R)-西布曲明硫酸盐由于与传统的(R,S)-西布曲明盐酸单水合物相比，具有显著的高水溶性和优异的抗潮湿和高温稳定性，因此可用作制药组合物的活性成分。此外，本发明的制备方法从工艺角度来看方便且经济。
• Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
  申请人：——

  公开号：US20020006963A1

  公开（公告）日：2002-01-17

  This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. The invention further encompasses pharmaceutical compositions and dosage forms which comprise optically pure (−) sibutramine, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor.

  本发明涵盖了治疗和预防多种疾病的方法，包括但不限于：进食障碍；体重增加；肥胖症；肠易激综合征；强迫症；血小板粘附；呼吸暂停；情感障碍，如注意力缺陷障碍、抑郁症和焦虑症；男性和女性性功能障碍；不宁腿综合症；骨关节炎；物质滥用，包括尼古丁和可卡因成瘾；嗜睡症；疼痛，如神经病性疼痛、糖尿病神经病变和慢性疼痛；偏头痛；脑功能障碍；经前综合症和失禁。该发明还涵盖了药物组合物和剂型，其中包括光学纯（-）西布曲明，可选配磷酸二酯酶抑制剂或脂肪酶抑制剂。
• Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
  申请人：——

  公开号：US20020006964A1

  公开（公告）日：2002-01-17

  This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. The invention further encompasses pharmaceutical compositions and dosage forms which comprise optically pure (+) sibutramine, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor.

  本发明涵盖了治疗和预防多种疾病的方法，包括但不限于：进食障碍；体重增加；肥胖症；肠易激综合征；强迫症；血小板粘附；呼吸暂停；情感障碍，如注意力缺陷障碍、抑郁症和焦虑症；男性和女性性功能障碍；不宁腿综合征；骨关节炎；药物滥用，包括尼古丁和可卡因成瘾；嗜睡症；疼痛，如神经病性疼痛、糖尿病神经病变和慢性疼痛；偏头痛；脑功能障碍；经前综合征和失禁。本发明还涵盖了含有光学纯(+)西布曲明的制药组合物和剂型，可选地与磷酸二酯酶抑制剂或脂肪酶抑制剂结合使用。